Massimiliano (Max) Mazzone graduated in Medical Biotechnology at the Medical School of the University of Torino, Italy, and then performed his PhD in Cell Science and Technologies at the Institute for Cancer Research of Torino, under the supervision of Prof. Comoglio. In November 2006, he moved to Belgium as an EMBO-awarded postdoctoral fellow in the lab of Prof. Peter Carmeliet, at the University of Leuven, Belgium. Since September 2009, he is heading the Lab of Molecular Oncology and Angiogenesis, at the Vesalius Research Center, part of the VIB in Leuven, and he is Associate Professor at the University of Leuven.
Max Mazzone has contributed to the field of oncology understanding the mechanisms of cancer metastasis and to vascular biology identifying a new endothelial cell phenotype, the "phalanx" cell, which takes part in the formation of aligned blood vessels in perfused tissues. Since he is independent group leader, his team is focusing in studying the response of inflammatory cells to hypoxic conditions in order to restore blood flow and regulate favorably the immune response in conditions such as cancer and ischemic pathologies.
Max got important national awards (the Belgian Royal Academy Prize, the Italian Lorini Award, and the AIRC Price for excellence in science, etc.) and international recognitions (ERC, EMBO, FEBS, Burgen Award, etc.). He is author in 61 papers, with an average impact factor in first or senior corresponding author research papers of 21, 6000 total citations, and an H-index of 31. He is member of the boards of several peer-reviewd journals (such as Cancer Research), he is reviewer for almost 20 journals, and he has been so far invited to speak in more than 60 national and international conferences (including GRC, Keystone, AACR, FEBS meetings, etc.). He currently holds an ERC starting grant and EMBO Young Investigator Award.